Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (1-10 of 367) with videos related to

Pageof 37
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 13, 2017
How should "RET positive" NSCLC be treated?Egbert F Smit
Future Oncology (London, England)|July 16, 2024
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 studyEgbert F Smit
Nature Reviews. Clinical Oncology|January 1, 2016
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targetsEgbert F Smit, Paul Baas
The Oncologist|May 2, 2007
Design of clinical trials of radiation combined with antiangiogenic therapySuresh Senan, Egbert F Smit
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?Egbert F Smit, Jose Belderbos
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Update on the systemic treatment of lung cancerGiuseppe Giaccone, Egbert F Smit
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2023
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?Frank J Borm, Egbert F Smit
Journal of Thoracic Disease|December 23, 2017
Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?Pieter E Postmus, Egbert F Smit
Oncology|July 5, 2014
Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitorsJustine L Kuiper, Egbert F Smit
Therapeutic Advances in Medical Oncology|February 17, 2017
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implicationsAdrianus J de Langen, Egbert F Smit
Pageof 37

Showing results (1-10 of 367) with videos related to

Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|February 13, 2017
How should "RET positive" NSCLC be treated?Egbert F Smit
Future Oncology (London, England)|July 16, 2024
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 studyEgbert F Smit
Nature Reviews. Clinical Oncology|January 1, 2016
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targetsEgbert F Smit, Paul Baas
The Oncologist|May 2, 2007
Design of clinical trials of radiation combined with antiangiogenic therapySuresh Senan, Egbert F Smit
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?Egbert F Smit, Jose Belderbos
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Update on the systemic treatment of lung cancerGiuseppe Giaccone, Egbert F Smit
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2023
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?Frank J Borm, Egbert F Smit
Journal of Thoracic Disease|December 23, 2017
Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?Pieter E Postmus, Egbert F Smit
Oncology|July 5, 2014
Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitorsJustine L Kuiper, Egbert F Smit
Therapeutic Advances in Medical Oncology|February 17, 2017
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implicationsAdrianus J de Langen, Egbert F Smit
Pageof 37